

S9 Table. Reasons for ineligibility in the PACIFIC trial

Key inclusion of exclusion criteria of PACIFIC trial	Ineligible for PACIFIC criteria	
	No. (%)	Received durvalumab (n)
Inclusion criteria		
Stage III, locally advanced, unresectable NSCLC	17 (9.9)	4
ECOG PS of 0 or 1	17 (9.9)	9
Durvalumab within 42 days from the end of the CCRT	17 (9.9)	17
Total RT dose of 60 Gy \pm 10% (54 Gy to 66 Gy)	9 (5.3)	3
Mean lung dose must be < 20 Gy	11 (6.4)	7
Lung V20 must be < 35%	19 (11.1)	12
Mean esophagus dose must be < 34 Gy	11 (6.4)	4
Heart V45 < 35% or V30 < 30%	13 (7.6)	8
Adequate organ and marrow function	8 (4.7)	4
Exclusion criteria		
Previous malignancy	8 (4.7)	4
Known history of tuberculosis	17 (9.9)	6
Radiation pneumonitis (grade \geq 2)	8 (4.7)	4
Total	100 (58.5)	49

CCRT, concurrent chemoradiation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RT, radiation therapy; V20, volume of lung receiving at least 20 Gy; V30, volume of heart receiving at least 30 Gy; V45, volume of heart receiving at least 45 Gy.